Key Takeaways
- Volume-led growth, margin miss on one-off costs: Revenue grew +7.9% YoY driven by non-Ibuprofen pharma volumes, but EBITDA margin fell short of the 13-14% target due to an unexpected INR7-8 crores fuel cost spike from Punjab floods.
- Paracetamol ramp is the growth engine: The new 11,800 MT facility hit 55-60% utilization in six months, already exceeding last year's full capacity, with 65% targeted by March.
- Profitability reset expected from Q3: The INR6 crores one-off employee variable payout and INR7-8 crores abnormal fuel cost both drop out, setting up a sequential margin recovery management calls "more profitable upcoming quarters."
- FY27 ambition laid down: Management targets INR2,600-2,700 crores revenue with 13-15% EBITDA margin, implying a 1-2% annual margin expansion from a base it hasn't yet consistently delivered.
- What to watch next quarter: Whether power costs actually normalize by the promised INR5-6 crores, whether non-Ibuprofen export volumes pick up as guided, and whether H2 revenue growth hits the 10-12% needed to land near the full-year target.
Paracetamol Scale-Up
- Capacity leap: Enhanced from 3,600 MT to 11,800 MT in March 2025, the new facility reached 55-60% utilization within the first six months and has already crossed last year's total output.
- Demand bucking the market: Management acknowledged the overall paracetamol market is weak but said IOL's demand is increasing, with the product "getting good traction" even though prices remain subdued.
- March target: Utilization expected to reach 65% by fiscal year-end, implying continued volume contribution in H2.
- Captive integration benefit: As paracetamol production scales, captive consumption of acetic anhydride (an intermediate) will grow internally, supporting chemical segment volumes.
Mahajan: "As regard to -- as you've rightly said that the demand of paracetamol is not increasing but as for IOL is concerned, our demand is increasing to some extent as earlier capacity of paracetamol was 3,600 metric ton. But in March '25, we've started -- enhanced capacity of 11,800 and we've already reached around 55% to 60% capacity utilization for -- you can say in the first 6 months, we have already crossed last year capacity."
Margin Bridge: The Q2 Miss
- The fuel shock: Heavy rains and floods in Punjab rendered rice husk (the basic raw material for power and steam) unusable due to moisture, forcing IOL to burn costlier alternative fuels and grid power. The impact: INR7-8 crores, or roughly 1% of margin.
- One-off employee cost: Employee benefit expenses spiked INR5 crores (INR6 crores impact cited elsewhere) from year-end variable payments and incentives that land entirely in Q2. This will not recur in Q3 or Q4.
- Chemicals margin offset: The chemicals segment saw EBIT margin improvement from buying negotiations, inventory accumulation at lower prices (inventory gain), and efficiency improvements, partially cushioning the pharma-side hit.
- Normalization bet: Management hopes power costs reduce by INR5-6 crores in the current quarter (Q3), returning to near-normal levels, though no firm timeline was committed.
Khanna: "Actually, regarding EBITDA margin, we expect and declared the target in the previous con calls about 13% to 14% but we are not able to achieve the target in the quarter due to unexpected rise in fuel costs, due to heavy rains and floods."
Non-Ibuprofen Pharma & Pipeline
- Current drivers: Paracetamol, Clopidogrel, Pantoprazole and a few non-API products drove growth in the non-Ibuprofen portfolio, which is the company's stated mix-shift priority.
- Mix target: Management wants to reach a 50:50 split between Ibuprofen and other pharma products in coming years, reducing dependence on the legacy molecule.
- Sitagliptin shelved: Despite having EDQM approval and a patent, IOL is not pushing Sitagliptin Phosphate Monohydrate because a price war has driven market prices below the cost of production.
- Apixaban early-stage: Patent filed, product developed only to pilot phase; no commercial production yet.
- Sartans in the queue: Olmesartan and Candesartan are being worked on; production will happen in the multiproduct facility as and when orders are received.
- Pipeline depth: Nine more drugs are in the pipeline at R&D scale, though management declined to name them or specify therapeutic areas, saying molecules are selected based on market demand-supply gaps rather than a segment strategy.
Rana: "As of now, we are not doing this because of the price war in the market because whatever the price is there in the market, that is not even the cost of production."
Revenue Growth & Mix
| Driver | Trend | Commentary |
|---|---|---|
| Non-Ibuprofen pharma | ▲ Volume growth | Paracetamol, Clopidogrel, Pantoprazole leading; export optimism for Q3/Q4. |
| Ibuprofen | ▬ Stable | Small U.S. exports; no tariff impact as generics are exempt. |
| Chemicals | ▬ Flattish | Volume gains offset by pricing pressure; margin improved on procurement gains. |
| Domestic share | ▲ Rising | Increased to 76% of H1 revenue (from 74% in Q1) as higher paracetamol capacity fed domestic supply; export value roughly flat. |
- H1 vs guidance: H1 revenue grew around 9%, slightly short of the 10-12% full-year target. Management expects H2 to deliver 10-12% growth, with the full year landing "very close" to the target but possibly a little short.
- Export catalyst: Management is "very hopeful and optimistic" that non-Ibuprofen export sales will increase in both Q3 and Q4, supported by the new U.K. subsidiary (IOL Pharmaxis UK Limited) incorporated to stay near European customers and respond faster to their requirements.
Singh: "I think a little bit we could not reach to that level within this H1. But for H2, we are hopeful that we will be achieving 10%, 12% from now, maybe a little bit short as compared to the whole year, but we are -- we will be reaching very close to that."
Regulatory & Market Access
- Europe: All IOL products have CEP approval. Pantoprazole Sodium Process-III received an amended EDQM Certificate of Suitability; samples already sent to customers with approval processes underway.
- U.S. footprint: Metformin and Fenofibrate hold U.S. FDA approval. Ibuprofen is exported to the U.S. in very small amounts. Management confirmed all three have approval but did not clarify current export volumes for Metformin and Fenofibrate.
- U.S. tariffs: No impact because tariffs apply to branded and other products, not generics; all IOL products are generic.
- Other markets: Approvals in place for Brazil, Korea, Russia and other regions.
- U.S. ramp timeline: Impact from U.S. FDA approvals will materialize "as and when commercial quantities are supplied to U.S. customers regularly, which will come with the passage of time, not instantly."
Costs, Capex & Balance Sheet
- Power & fuel normalization: Management hopes the current quarter (Q3) sees power costs reduce by INR5-6 crores toward normal levels.
- Employee cost base: The INR6 crores variable-pay spike in Q2 will not repeat in Q3 and Q4, mechanically lifting profitability.
- Input cost strategy: IOL is negotiating directly with manufacturers in China for best prices and expects "better opportunity" ahead, though no quantified benefit was given.
- Capex run-rate: INR150-200 crores annually covering growth capex, infrastructure, land, software and automation. H1 saw INR60 crores deployed; ~INR100 crores expected in H2.
- Land acquisition: A land parcel near the Chandigarh-Bathinda Highway is progressing through regulatory approvals; some received, 2-3 pending. All approvals expected within two quarters, on track with the original eight-quarter timeline.
- Seasonal profitability pattern: Q2 is described as "the bad quarter" and Q4 as "the best," implying a back-end-loaded earnings profile.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Paracetamol capacity utilization | Reach 65% (from current 55%) | By March 2025 end |
| H2 revenue growth | Achieve 10-12% growth | H2 FY26 |
| Power cost normalization | Reduce by INR5-6 crores toward normal levels | Current quarter (Q3 FY26) |
| Land regulatory approvals | All pending approvals received | Within 2 quarters |
| FY27 revenue target | INR2,600-2,700 crores | FY27 |
| FY27 EBITDA margin target | 13% to 15% | FY27 |
| Annual revenue growth ambition | 10% to 15% every year | Ongoing |
| Annual EBITDA margin expansion | 1% to 2% increase every year | Ongoing |
| Pharma mix target | 50% Ibuprofen, 50% other pharma products | "Coming years" |
| Non-Ibuprofen export growth | Definite increase | Q3 and Q4 FY26 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations | ₹567.5 cr, 7.9% YoY growth |
| EBITDA margin | 11.8% in H1 FY26, up from 10.2% in H1 FY25; Q2 impacted ~1% by higher fuel costs |
| PAT growth | 33% YoY growth, driven by volume, product mix, and shift to regulated customers |
| Power and fuel cost impact | ₹7–8 cr incremental cost in Q2 due to floods, expected to normalize by ₹5–6 cr in Q3 |
| Employee variable pay impact | ~₹6 cr one-time impact in Q2, not recurring in Q3/Q4 |
| Pharma segment revenue mix | Ibuprofen 62%, other APIs 38% of pharma revenue |
| Overall revenue mix | Pharma 59%, Chemicals 41% |
| Paracetamol capacity utilization | 55% in Q2 (new 11,800 MT plant), target 65% by March 2026 |
| Ethyl acetate capacity utilization | ~100% |
| Acetic anhydride captive use | ~60% of production |
| Capex incurred in H1 FY26 | ~₹60 cr of the ₹150–200 cr full-year plan |
| Maintenance vs growth capex split | 40% maintenance, 60% growth |
| FY27 revenue target | ₹2,600–2,700 cr |
| FY27 EBITDA margin target | 13–15% |